GlassScriptPhysician profile
Heather B Roan
NPI 1558819532
$11,357.21
in general payments reported to CMS, 2019-2025
44 companies · $2,146 in 2025
The $2,146 reported for 2025 was more than what 92% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,041 · 2022: $2,632 · 2023: $1,563 · 2024: $2,974 · 2025: $2,146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,811 · Travel and Lodging: $855 · Education: $17.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,811.31 |
| Travel and Lodging | $855.20 |
| Education | $17.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,855.48 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Novo Nordisk INC | $921.34 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $855.68 | 2021-2025 | Mounjaro, Zepbound, Humulin |
| Corcept Therapeutics | $679.45 | 2021-2025 | Korlym |
| Insulet Corporation | $617.72 | 2021-2025 | Omnipod, Omnipod |
| Dexcom, INC. | $588.75 | 2021-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $440.65 | 2021-2025 | |
| Tandem Diabetes Care, INC. | $425.82 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Xeris Pharmaceuticals, INC. | $382.51 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Abbvie INC. | $379.54 | 2021-2025 | |
| Amgen INC. | $366.64 | 2021-2025 | Tepezza, Evenity, Prolia |
| Recordati_rare_diseases_inc. | $286.83 | 2021-2025 | Isturisa, Signifor Lar |
| Antares Pharma, INC. | $264.91 | 2021-2024 | Xyosted, Tlando, Nocdurna |
| Amarin Pharma, INC. | $225.10 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $190.73 | 2021-2023 | Contrave |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $168.06 | 2021-2024 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $146.49 | 2021-2025 | |
| Horizon Therapeutics Plc | $141.15 | 2022-2023 | Tepezza |
| Radius Health, INC. | $138.70 | 2021-2025 | Tymlos |
| Pfizer INC. | $106.95 | 2022-2025 | |
| Ibsa Pharma INC. | $105.80 | 2021-2023 | Tirosint, Licart |
| Ascendis Pharma Endocrinology INC | $97.86 | 2023-2025 | Yorvipath |
| Acella Pharmaceuticals, LLC | $97.65 | 2022-2025 | NP Thyroid 60 |
| Nevro Corp. | $84.34 | 2022-2023 | Senza |
| Merck Sharp & Dohme LLC | $81.60 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.77 | 2021-2025 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $73.20 | 2021-2023 | Livalo, Seglentis |
| Astrazeneca Pharmaceuticals LP | $63.55 | 2021-2022 | |
| Sequel Med Tech, LLC | $63.02 | 2025 | Twiist |
| Regeneron Healthcare Solutions, INC. | $59.96 | 2025 | Evkeeza |
| Averitas Pharma INC. | $51.30 | 2024 | Qutenza |
| Madrigal Pharmaceuticals | $50.13 | 2025 | Rezdiffra |
| Eusa Pharma (US) LLC | $37.99 | 2022 | |
| Kyowa Kirin, INC. | $32.84 | 2023-2024 | Crysvita |
| Clarus Therapeutics INC. | $31.72 | 2021 | |
| Halozyme INC | $24.71 | 2023 | |
| Beta Bionics, INC. | $20.17 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Chiesi USA, INC. | $19.16 | 2025 | Mycapssa |
| Esperion Therapeutics, INC. | $19.05 | 2022 | |
| Opko Pharmaceuticals, LLC | $17.48 | 2023 | Rayaldee |
| Rhythm Pharmaceuticals, INC. | $17.01 | 2025 | Imcivree |
| Vifor Pharma, INC. | $16.92 | 2021 | |
| Grt US Holding, INC. | $16.88 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $16.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Roan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.